PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$62.79 USD
+1.36 (2.21%)
Updated May 7, 2024 04:00 PM ET
After-Market: $64.01 +1.22 (1.94%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRCT 62.79 +1.36(2.21%)
Will PRCT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Other News for PRCT
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Procept BioRobotics price target raised by $8 at Piper Sandler, here's why
Procept BioRobotics announces long-term, real-world data on Aquablation